Darolutamide
- Generic Name
- Darolutamide
- Brand Names
- Nubeqa
- Drug Type
- Small Molecule
- Chemical Formula
- C19H19ClN6O2
- CAS Number
- 1297538-32-9
- Unique Ingredient Identifier
- X05U0N2RCO
- Background
Darolutamide is a nonsteroidal androgen receptor antagonist for the treatment of castrate-resistant, non-metastatic prostate cancer (nmCRPC). This condition occurs in the majority of patients with advanced prostate cancer who have been treated with androgen receptor antagonists. Though prior treatment for prostate cancer has been successful for these patient...
- Indication
Darolutamide is indicated for the treatment of adults with non-metastatic castration-resistant prostate cancer (nmCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC) in combination with docetaxel.
- Associated Conditions
- Metastatic Hormone-Sensitive Prostate Cancer (mHSPC), Non-Metastatic Castration-Resistant Prostate Cancer
- Associated Therapies
- -
Testing the Anti-Cancer Drug Darolutamide in Patients With Testosterone-driven Salivary Gland Cancers
- Conditions
- Interventions
- First Posted Date
- 2023-01-03
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT05669664
- Locations
- 🇺🇸
UCI Health - Chao Family Comprehensive Cancer Center and Ambulatory Care, Irvine, California, United States
🇺🇸Los Angeles General Medical Center, Los Angeles, California, United States
🇺🇸USC / Norris Comprehensive Cancer Center, Los Angeles, California, United States
Neo-DAB: Darolutamide and Abemaciclib in Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-11-16
- Last Posted Date
- 2024-08-20
- Lead Sponsor
- Praful Ravi, MB BCHir, MRCP
- Target Recruit Count
- 9
- Registration Number
- NCT05617885
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-05-10
- Last Posted Date
- 2024-12-18
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 190
- Registration Number
- NCT05367440
- Locations
- 🇬🇧
Research Site, Plymouth, United Kingdom
TT-702 in Patients With Advanced Solid Tumours.
- First Posted Date
- 2022-03-09
- Last Posted Date
- 2024-05-13
- Lead Sponsor
- Cancer Research UK
- Target Recruit Count
- 188
- Registration Number
- NCT05272709
- Locations
- 🇬🇧
The Christie NHS Foundation Trust, Manchester, United Kingdom
🇬🇧Royal Marsden Hospital NHS Foundation Trust, London, United Kingdom
🇬🇧University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score
- First Posted Date
- 2021-09-20
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- NRG Oncology
- Target Recruit Count
- 2050
- Registration Number
- NCT05050084
- Locations
- 🇺🇸
Arizona Center for Cancer Care - Gilbert, Gilbert, Arizona, United States
🇺🇸Arizona Center for Cancer Care-Peoria, Peoria, Arizona, United States
🇺🇸Arizona Center for Cancer Care - Phoenix, Phoenix, Arizona, United States
Psma Intensity Can be Altered by Androgen and Phospho-SrC Obstruction
- First Posted Date
- 2021-06-14
- Last Posted Date
- 2023-04-12
- Lead Sponsor
- St Vincent's Hospital, Sydney
- Target Recruit Count
- 22
- Registration Number
- NCT04925648
- Locations
- 🇦🇺
Kinghorn Cancer Centre, St. Vincent's Hospital, Sydney, New South Wales, Australia
🇦🇺Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
Neoadjuvant Androgen Deprivation, Darolutamide, and Ipatasertib in Men With Localized, High Risk Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2021-02-03
- Last Posted Date
- 2023-11-13
- Lead Sponsor
- David VanderWeele
- Target Recruit Count
- 6
- Registration Number
- NCT04737109
- Locations
- 🇺🇸
Penn State Cancer Institute, Hershey, Pennsylvania, United States
🇺🇸Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States
🇺🇸Indiana University Melvin and Bren Simon Comprehensive Cancer Center, Indianapolis, Indiana, United States
Stereotactic Body Radiotherapy With or Without Darolutamide for OligoRecurrent Prostate Cancer
- Conditions
- Interventions
- First Posted Date
- 2020-11-23
- Last Posted Date
- 2024-02-28
- Lead Sponsor
- University Hospital, Ghent
- Target Recruit Count
- 124
- Registration Number
- NCT04641078
- Locations
- 🇧🇪
AZ St-Jan Brugge, Brugge, Belgium
🇧🇪AZ St-Lucas Gent, Gent, Belgium
🇧🇪Ghent University Hospital, Ghent, Belgium
Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial)
- Conditions
- Interventions
- First Posted Date
- 2020-09-22
- Last Posted Date
- 2024-04-02
- Lead Sponsor
- Latin American Cooperative Oncology Group
- Target Recruit Count
- 51
- Registration Number
- NCT04558866
- Locations
- 🇧🇷
CTTB - Centro de Tratamento de Tumores Botafogo (Oncoclínicas), Rio De Janeiro, Brazil
🇧🇷HMV - Hospital Moinhos de Vento, Porto Alegre, Rio Grande Do Sul, Brazil
🇧🇷Hospital Sírio-Libanês SP, São Paulo, Brazil
Testing the Addition of Darolutamide to Hormonal Therapy (Androgen Deprivation Therapy [ADT]) After Surgery for Men With High-Risk Prostate Cancer, The ERADICATE Study
- Conditions
- Interventions
- First Posted Date
- 2020-07-24
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- ECOG-ACRIN Cancer Research Group
- Target Recruit Count
- 27
- Registration Number
- NCT04484818
- Locations
- 🇺🇸
Indiana University/Melvin and Bren Simon Cancer Center, Indianapolis, Indiana, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸Los Angeles County-USC Medical Center, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.